Form 8-K - Current report:
SEC Accession No. 0001104659-25-105223
Filing Date
2025-11-03
Accepted
2025-11-03 07:06:14
Documents
14
Period of Report
2025-11-03
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K qure-20251103x8k.htm   iXBRL 8-K 42101
2 EX-99.1 qure-20251103xex99d1.htm EX-99.1 21491
3 GRAPHIC qure-20251103xex99d1001.jpg GRAPHIC 4844
  Complete submission text file 0001104659-25-105223.txt   186009

Data Files

Seq Description Document Type Size
4 EX-101.SCH qure-20251103.xsd EX-101.SCH 2676
5 EX-101.LAB qure-20251103_lab.xml EX-101.LAB 15213
6 EX-101.PRE qure-20251103_pre.xml EX-101.PRE 9963
16 EXTRACTED XBRL INSTANCE DOCUMENT qure-20251103x8k_htm.xml XML 4645
Mailing Address PAASHEUVELWEG 25A AMSTERDAM Netherlands 1105 BP
Business Address PAASHEUVELWEG 25A AMSTERDAM Netherlands 1105 BP 1-339-970-7000
uniQure N.V. (Filer) CIK: 0001590560 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36294 | Film No.: 251442084
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)